Bellevue Group’s Roivant Sciences ROIV Stock Holding History

Bellevue Group’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-108,039	Closed	-$2.34M	–	188
2025 Q4	$2.34M	Buy	+108,039	New	+$2.13M	0.04%	93
2025 Q1	–	Sell	-24,000	Closed	-$284K	–	163
2024 Q4	$284K	Buy	+24,000	New	+$284K	0.01%	138

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bellevue Group's ROIV Position: Q1 2026 in Review

Bellevue Group sold out of Roivant Sciences (ROIV) in Q1 2026, closing a stake of 108,039 shares — an estimated $2.34M sold.

Bellevue Group first reported a position in ROIV in Q4 2024 and held it in 2 quarters. The position peaked at $2.34M in Q4 2025. 444 funds tracked by Wall St. Rank hold ROIV as of Q1 2026.

Bellevue Group reported no remaining Roivant Sciences position as of Q1 2026 after selling out during the quarter.
Bellevue Group sold 108,039 Roivant Sciences shares in Q1 2026, an estimated $2.34M.
Bellevue Group first reported a position in Roivant Sciences in Q4 2024 and held it in 2 quarters.
Bellevue Group's Roivant Sciences position peaked at $2.34M in Q4 2025.
444 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.